A Phase 3 interventional study of BMS-663068 and Placebo in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 139 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 35th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2015, is one of 65 in phase 3, reaches primary completion later than 0 of the 26 other live ones, and was the 161st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 10 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 371 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Drug: BMS-663068
Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Drug: BMS-663068 · Other: Placebo
BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Drug: BMS-663068
BMS-663068
Placebo
Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort
Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Time frame: Day 1 and Day 8
Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort
The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.
Time frame: Day 1 and Day 8
Percentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort
The durability of response (that is, the number of participants achieving HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: At Weeks 24, 48 and 96
Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort
An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: Up to Week 96 analysis cut-off date
Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort
Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: Baseline and up to Week 96 analysis cut-off date
Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort
Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: Baseline and up to Week 96 analysis cut-off date
Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort
Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: Up to Week 96 analysis cut-off date
Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Time frame: Day 1 and Day 8
Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Time frame: Day 1 and Day 8
Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort
Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Change From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort
CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Change From Baseline in CD4+ T- Cell Count Percentage Through Week 96
Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort
Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at any time after prior confirmed suppression to \<400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, \> 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is \>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at or after Week 24.
Time frame: Week 96
Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort
The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR\<1 indicates that FC is smaller on-treatment than at Baseline. FCR \>3 indicates that on-treatment FC is 3 times greater than it was at Baseline.
Time frame: Week 96
This was a 2 cohort Phase 3 study conducted in heavily treatment experienced (HTE) participants infected with multi-drug resistant human immunodeficiency virus (HIV)-1. Participants were assigned to either the Randomized Cohort (participants received either fostemsavir or placebo) or Non-randomized Cohort (all participants received fostemsavir).
| Milestone | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID-Open Label Period |
|---|---|---|---|
| Started | 69 | 203 | 0 |
| Completed | 68 | 199 | 0 |
| Not completed | 1 | 4 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: No longer meets study criteria | 0 | 1 | 0 |
| Milestone | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID-Open Label Period |
|---|---|---|---|
| Started | 68 | 199 | 99 |
| Completed | 0 | 0 | 0 |
| Not completed | 68 | 199 | 99 |
| Withdrew: Other | 0 | 1 | 1 |
| Withdrew: No longer meets criteria | 0 | 4 | 4 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 8 | 6 |
| Withdrew: Lost to follow-up | 4 | 3 | 1 |
| Withdrew: Death | 1 | 7 | 15 |
| Withdrew: Withdrawal by subject | 0 | 5 | 1 |
| Withdrew: Adverse event | 3 | 2 | 4 |
| Withdrew: Lack of efficacy | 3 | 9 | 6 |
| Withdrew: Ongoing at the time of analysis | 54 | 159 | 61 |
Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.
| Log10 copies per milliliter (c/mL) | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID |
|---|---|---|
| Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort | -0.166 (-0.326 to -0.007) | -0.791 (-0.885 to -0.698) |
The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.
| Percentage of participants | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID |
|---|---|---|
| >0.5 log10 c/mL | 18.84 (11.35 to 29.61) | 64.53 (57.74 to 70.79) |
| >1.0 log10 c/mL | 10.14 (5.00 to 19.49) | 45.81 (39.10 to 52.68) |
The durability of response (that is, the number of participants achieving HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Percentage of participants | Randomized Cohort |
|---|---|
| Week 24 | 53 (47.0 to 58.8) |
| Week 48 | 54 (47.7 to 59.5) |
| Week 96 | 60 (54.0 to 65.6) |
An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Participants | Randomized Cohort |
|---|---|
| SAE | 92 |
| AELD | 14 |
Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Participants | Randomized Cohort |
|---|---|
| Albumin; n=268 | 1 |
| Alkaline phosphatase; n=268 | 3 |
| Alanine aminotransferase; n=268 | 14 |
| Amylase; n=268 | 2 |
| Aspartate aminotransferase; n=268 | 10 |
| Bicarbonate; n=268 | 1 |
| Direct bilirubin; n=268 | 20 |
| Bilirubin; n=268 | 7 |
| Calcium; n=268 | 9 |
| Cholesterol; n=221 | 10 |
| Creatine kinase; n=268 | 6 |
| Creatinine; n=268 | 52 |
| Estimated creatinine clearance; n=268 | 75 |
| Glucose/hyperglycemia; n=267 | 6 |
| Glucose/hypoglycemia; n=267 | 2 |
| Potassium/hyperkalemia; n=268 | 4 |
| Potassium/hypokalemia; n=268 | 0 |
| Low density lipoprotein (LDL) cholesterol; n=216 | 8 |
| Lipase; n=268 | 13 |
| Sodium/hypernatremia; n=268 | 0 |
| Sodium/hyponatremia; n=268 | 0 |
| Triglycerides; n=221 | 11 |
| Urate; n=268 | 9 |
Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Participants | Randomized Cohort |
|---|---|
| Hemoglobin; n=268 | 16 |
| Neutrophils; n=268 | 10 |
| Platelets; n=267 | 2 |
| Leukocytes; n=268 | 4 |
Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Participants | Randomized Cohort |
|---|---|
| Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort | 23 |
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
| Cells per cubic millimeter | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID |
|---|---|---|
| Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort | 18.9 (4.7 to 33.0) | 18.5 (10.1 to 26.8) |
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
| Percentage of CD4+T- cells | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID |
|---|---|---|
| Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort | 0.243 (-0.216 to 0.703) | 0.860 (0.588 to 1.133) |
Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
| Log10 c/mL | Randomized Cohort |
|---|---|
| Day 8; n=262 | -0.656 ± 0.7536 |
| Week 4; n=262 | -2.051 ± 1.0717 |
| Week 8; n=256 | -2.207 ± 1.1416 |
| Week 12; n=248 | -2.237 ± 1.2105 |
| Week 16; n=249 | -2.277 ± 1.2834 |
| Week 24; n=246 | -2.297 ± 1.2788 |
| Week 36; n=238 | -2.332 ± 1.2265 |
| Week 48; n=233 | -2.324 ± 1.2876 |
| Week 60; n=223 | -2.419 ± 1.1973 |
| Week 72; n=221 | -2.427 ± 1.1542 |
| Week 84; n=215 | -2.455 ± 1.1930 |
| Week 96; n=214 | -2.476 ± 1.1984 |
CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
| Cells per cubic millimeter | Randomized Cohort |
|---|---|
| Day 8; n=255 | 19.8 ± 60.98 |
| Week 4; n=259 | 48.9 ± 131.75 |
| Week 8; n=254 | 61.5 ± 113.47 |
| Week 12; n=249 | 79.0 ± 123.31 |
| Week 16; n=245 | 84.1 ± 107.26 |
| Week 24; n=247 | 90.4 ± 112.10 |
| Week 36; n=234 | 109.7 ± 119.50 |
| Week 48; n=228 | 138.9 ± 135.06 |
| Week 60; n=215 | 162.9 ± 157.69 |
| Week 72; n=217 | 172.1 ± 184.81 |
| Week 84; n=203 | 190.8 ± 165.63 |
| Week 96; n=213 | 204.7 ± 191.28 |
Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
| Percentage of CD4+ T- cells | Randomized Cohort |
|---|---|
| Day 8; n=255 | 0.75 ± 1.970 |
| Week 4; n=259 | 2.30 ± 4.643 |
| Week 8; n=254 | 2.36 ± 4.392 |
| Week 12; n=249 | 3.00 ± 4.945 |
| Week 16; n=245 | 3.51 ± 4.979 |
| Week 24; n=247 | 4.26 ± 4.828 |
| Week 36; n=234 | 5.06 ± 5.256 |
| Week 48; n=228 | 6.51 ± 5.531 |
| Week 60; n=215 | 7.00 ± 5.940 |
| Week 72; n=217 | 7.02 ± 5.726 |
| Week 84; n=203 | 7.68 ± 5.798 |
| Week 96; n=213 | 8.44 ± 6.409 |
Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at any time after prior confirmed suppression to \<400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, \> 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is \>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at or after Week 24.
| Participants | Randomized Cohort |
|---|---|
| Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort | 24 |
The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR\<1 indicates that FC is smaller on-treatment than at Baseline. FCR \>3 indicates that on-treatment FC is 3 times greater than it was at Baseline.
| Participants | Randomized Cohort |
|---|---|
| <=1 | 19 |
| >1 to 3 | 10 |
| >3 to 10 | 5 |
| >10 to 100 | 1 |
| >100 to 3000 | 10 |
| >3000 | 8 |
Collected over On-treatment non-SAEs and SAEs were collected from the start of study treatment until Week 96 data cut-off date. The data presented for Randomized Cohort-Placebo and Randomized Cohort-fostemsavir 600 mg BID represent safety events during the double-blind period (Up to Day 8). The safety data presented in the Randomized Cohort-Total, Non-Randomized Cohort-fostemsavir 600 mg BID and Fostemsavir Total columns represent safety events during fostemsavir dosing until the Week 96 data cut-off date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Cohort-Placebo | 2/69 (2.9%) | 2/69 (2.9%) | 16/69 (23.2%) |
| Randomized Cohort-fostemsavir 600 mg BID | 10/203 (4.9%) | 4/203 (2%) | 45/203 (22.2%) |
| Non-randomized Cohort-fostemsavir 600 mg BID | 17/99 (17.2%) | 48/99 (48.5%) | 92/99 (92.9%) |
| Randomized Cohort-Total | 12/271 (4.4%) | 92/271 (33.9%) | 214/271 (79%) |
| Total Fostemsavir | 29/370 (7.8%) | 140/370 (37.8%) | 306/370 (82.7%) |
| Event | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID | Randomized Cohort-Total | Total Fostemsavir |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/69 | 2/203 | 3/99 | 12/271 | 15/370 |
| Acute kidney injuryRenal and urinary disorders | 0/69 | 0/203 | 4/99 | 2/271 | 6/370 |
| CellulitisInfections and infestations | 0/69 | 0/203 | 3/99 | 5/271 | 8/370 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/69 | 0/203 | 3/99 | 1/271 | 4/370 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/69 | 0/203 | 3/99 | 1/271 | 4/370 |
| SepsisInfections and infestations | 0/69 | 0/203 | 3/99 | 1/271 | 4/370 |
| Deep vein thrombosisVascular disorders | 0/69 | 0/203 | 2/99 | 1/271 | 3/370 |
| PyrexiaGeneral disorders | 0/69 | 0/203 | 2/99 | 1/271 | 3/370 |
| SeizureNervous system disorders | 0/69 | 0/203 | 2/99 | 1/271 | 3/370 |
| AstheniaGeneral disorders | 0/69 | 0/203 | 2/99 | 0/271 | 2/370 |
| Event | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID | Randomized Cohort-Total | Total Fostemsavir |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/69 | 8/203 | 25/99 | 60/271 | 85/370 |
| NauseaGastrointestinal disorders | 4/69 | 14/203 | 21/99 | 45/271 | 66/370 |
| NasopharyngitisInfections and infestations | 0/69 | 2/203 | 19/99 | 34/271 | 53/370 |
| PyrexiaGeneral disorders | 1/69 | 1/203 | 16/99 | 30/271 | 46/370 |
| FatigueGeneral disorders | 2/69 | 3/203 | 16/99 | 18/271 | 34/370 |
| Upper respiratory tract infectionInfections and infestations | 0/69 | 1/203 | 15/99 | 42/271 | 57/370 |
| HeadacheNervous system disorders | 5/69 | 6/203 | 12/99 | 36/271 | 48/370 |
| InfluenzaInfections and infestations | 0/69 | 1/203 | 13/99 | 26/271 | 39/370 |
| BronchitisInfections and infestations | 0/69 | 0/203 | 5/99 | 34/271 | 39/370 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/69 | 0/203 | 11/99 | 33/271 | 44/370 |
| Age, Continuous(Years) | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID-Open Label Period | Total |
|---|---|---|---|---|
| Mean | 43.0 ± 11.02 | 45.2 ± 12.72 | 48.1 ± 11.53 | 45.6 ± 12.20 |
| Sex: Female, Male(Participants) | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID-Open Label Period | Total |
|---|---|---|---|---|
| Female | 12 | 60 | 10 | 82 |
| Male | 57 | 143 | 89 | 289 |
| Race/Ethnicity, Customized(Participants) | Randomized Cohort-Placebo | Randomized Cohort-fostemsavir 600 mg BID | Non-randomized Cohort-fostemsavir 600 mg BID-Open Label Period | Total |
|---|---|---|---|---|
| Race customized — Black or African American | 18 | 42 | 23 | 83 |
| Race customized — American Indian or Alaska Native | 1 | 6 | 1 | 8 |
| Race customized — Asian | 0 | 2 | 0 | 2 |
| Race customized — Native Hawaiian or other Pacific islander | 0 | 1 | 0 | 1 |
| Race customized — White | 48 | 137 | 74 | 259 |
| Race customized — Mixed | 1 | 6 | 1 | 8 |
| Race customized — Hispanic | 0 | 2 | 0 | 2 |
| Race customized — Mestizo | 1 | 2 | 0 | 3 |
| Race customized — North African | 0 | 1 | 0 | 1 |
| Race customized — Mulatto | 0 | 1 | 0 | 1 |
| Race customized — Brown | 0 | 2 | 0 | 2 |
| Race customized — White and African descent | 0 | 1 | 0 | 1 |
Showing the first 100 of 139 sites across 25 countries. Choose a country and city above to see the rest.
Ran from Feb 2015 to primary completion in Aug 2016, 17 months.
Results were first posted in Sep 2018, 2 years 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 17 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fostemsavir